Blueprint Medicines Corp’s recently made public that its CHIEF EXECUTIVE OFFICER Haviland Kate unloaded Company’s shares for reported $0.16 million on Jan 21 ’25. In the deal valued at $110.24 per share,1,446 shares were sold. As a result of this transaction, Haviland Kate now holds 149,378 shares worth roughly $15.54 million.
Then, Rossi Christina sold 2,274 shares, generating $250,455 in total proceeds. Upon selling the shares at $110.14, the CHIEF OPERATING OFFICER now owns 67,109 shares.
Before that, Albers Jeffrey W. sold 15,161 shares. Blueprint Medicines Corp shares valued at $1,660,511 were divested by the Director at a price of $109.53 per share. As a result of the transaction, Albers Jeffrey W. now holds 152,396 shares, worth roughly $15.85 million.
JP Morgan initiated its Blueprint Medicines Corp [BPMC] rating to an Overweight in a research note published on November 14, 2024; the price target was $126. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in late October with a ‘”a Neutral”‘ rating. Stephens began covering BPMC with “an Overweight” recommendation on May 14, 2024. Leerink Partners revised its rating on May 06, 2024. It rated BPMC as “a Market perform” which previously was an “an Underperform”.
Price Performance Review of BPMC
On Monday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock fall -0.93% to $104.00. Over the last five days, the stock has lost -6.73%. Blueprint Medicines Corp shares have risen nearly 19.24% since the year began. Nevertheless, the stocks have risen 40.16% over the past one year. While a 52-week high of $121.90 was reached on 01/27/25, a 52-week low of $72.24 was recorded on 01/10/25. SMA at 50 days reached $99.51, while 200 days put it at $98.65.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 101.45, which if violated will result in even more drops to 98.91. On the upside, there is a resistance level at 105.85. A further resistance level may holdings at 107.70. The Relative Strength Index (RSI) on the 14-day chart is 46.48, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -5.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 81.45%. Stochastics %K at 20.59% indicates the stock is a holding.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2025-01-15, growing by 0.61 million shares to a total of 5.14 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 4.53 million shares. There was a rise of 11.94%, which implies that there is a positive sentiment for the stock.
